Cargando…
The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions
C-Kit (CD117), the receptor for the stem cell factor, a growth factor for melanocyte migration and proliferation, has shown differential immunostaining in various benign and malignant melanocytic lesions. The purpose of this study is to compare c-Kit immunostaining in benign nevi and in primary and...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284155/ https://www.ncbi.nlm.nih.gov/pubmed/22193299 http://dx.doi.org/10.4081/ejh.2011.e20 |
_version_ | 1782224326594920448 |
---|---|
author | Pilloni, L. Bianco, P. Difelice, E. Cabras, S. Castellanos, M.E. Atzori, L. Ferreli, C. Mulas, P. Nemolato, S. Faa, G. |
author_facet | Pilloni, L. Bianco, P. Difelice, E. Cabras, S. Castellanos, M.E. Atzori, L. Ferreli, C. Mulas, P. Nemolato, S. Faa, G. |
author_sort | Pilloni, L. |
collection | PubMed |
description | C-Kit (CD117), the receptor for the stem cell factor, a growth factor for melanocyte migration and proliferation, has shown differential immunostaining in various benign and malignant melanocytic lesions. The purpose of this study is to compare c-Kit immunostaining in benign nevi and in primary and metastatic malignant melanomas, to determine whether c-Kit can aid in the differential diagnosis of these lesions. c-Kit immunostaining was performed in 60 cases of pigmented lesions, including 39 benign nevi (5 blue nevi, 5 intra-dermal nevi, 3 junctional nevi, 15 cases of primary compound nevus, 11 cases of Spitz nevus), 18 cases of primary malignant melanoma and 3 cases of metastatic melanoma. The vast majority of nevi and melanomas examined in this study were positive for c-Kit, with minimal differences between benign and malignant lesions. C-Kit cytoplasmatic immunoreactivity in the intraepidermal proliferating nevus cells, was detected in benign pigmented lesions as well as in malignant melanoma, increasing with the age of patients (P=0.007) in both groups. The patient’s age at presentation appeared to be the variable able to cluster benign and malignant pigmented lesions. The percentage of c-Kit positive intraepidermal nevus cells was better associated with age despite other variables (P=0.014). The intensity and percentage of c-Kit positivity in the proliferating nevus cells in the dermis was significantly increased in malignant melanocytic lesions (P=0.015 and P=0.008) compared to benign lesions (compound melanocytic nevi, Spitz nevi, intradermal nevi, blue nevi). Immunostaning for c-Kit in metastatic melanomas was negative. Interestingly in two cases of melanoma occurring on a pre-existent nevus, the melanoma tumor cells showed strong cytoplasmatic and membranous positivity for c-kit, in contrast with the absence of any immunoreactivity in pre-existent intradermal nevus cells. C-Kit does not appear to be a strong immunohistochemical marker for distinguishing melanoma from melanocytic nevi, if we consider c-Kit expression in intraepidermal proliferating cells. The c-Kit expression in proliferating melanocytes in the dermis could help in the differential diagnosis between a superficial spreading melanoma (with dermis invasion) and a compound nevus or an intradermal nevus. Finally, c-Kit could be a good diagnostic tool for distinguishing benign compound nevi from malignant melanocytic lesions with dermis invasion and to differentiate metastatic melanoma from primary melanoma. |
format | Online Article Text |
id | pubmed-3284155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | PAGEPress Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-32841552012-02-23 The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions Pilloni, L. Bianco, P. Difelice, E. Cabras, S. Castellanos, M.E. Atzori, L. Ferreli, C. Mulas, P. Nemolato, S. Faa, G. Eur J Histochem Original Paper C-Kit (CD117), the receptor for the stem cell factor, a growth factor for melanocyte migration and proliferation, has shown differential immunostaining in various benign and malignant melanocytic lesions. The purpose of this study is to compare c-Kit immunostaining in benign nevi and in primary and metastatic malignant melanomas, to determine whether c-Kit can aid in the differential diagnosis of these lesions. c-Kit immunostaining was performed in 60 cases of pigmented lesions, including 39 benign nevi (5 blue nevi, 5 intra-dermal nevi, 3 junctional nevi, 15 cases of primary compound nevus, 11 cases of Spitz nevus), 18 cases of primary malignant melanoma and 3 cases of metastatic melanoma. The vast majority of nevi and melanomas examined in this study were positive for c-Kit, with minimal differences between benign and malignant lesions. C-Kit cytoplasmatic immunoreactivity in the intraepidermal proliferating nevus cells, was detected in benign pigmented lesions as well as in malignant melanoma, increasing with the age of patients (P=0.007) in both groups. The patient’s age at presentation appeared to be the variable able to cluster benign and malignant pigmented lesions. The percentage of c-Kit positive intraepidermal nevus cells was better associated with age despite other variables (P=0.014). The intensity and percentage of c-Kit positivity in the proliferating nevus cells in the dermis was significantly increased in malignant melanocytic lesions (P=0.015 and P=0.008) compared to benign lesions (compound melanocytic nevi, Spitz nevi, intradermal nevi, blue nevi). Immunostaning for c-Kit in metastatic melanomas was negative. Interestingly in two cases of melanoma occurring on a pre-existent nevus, the melanoma tumor cells showed strong cytoplasmatic and membranous positivity for c-kit, in contrast with the absence of any immunoreactivity in pre-existent intradermal nevus cells. C-Kit does not appear to be a strong immunohistochemical marker for distinguishing melanoma from melanocytic nevi, if we consider c-Kit expression in intraepidermal proliferating cells. The c-Kit expression in proliferating melanocytes in the dermis could help in the differential diagnosis between a superficial spreading melanoma (with dermis invasion) and a compound nevus or an intradermal nevus. Finally, c-Kit could be a good diagnostic tool for distinguishing benign compound nevi from malignant melanocytic lesions with dermis invasion and to differentiate metastatic melanoma from primary melanoma. PAGEPress Publications 2011-06-07 /pmc/articles/PMC3284155/ /pubmed/22193299 http://dx.doi.org/10.4081/ejh.2011.e20 Text en ©Copyright L. Pilloni et al., 2011 This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0). Licensee PAGEPress, Italy |
spellingShingle | Original Paper Pilloni, L. Bianco, P. Difelice, E. Cabras, S. Castellanos, M.E. Atzori, L. Ferreli, C. Mulas, P. Nemolato, S. Faa, G. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions |
title | The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions |
title_full | The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions |
title_fullStr | The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions |
title_full_unstemmed | The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions |
title_short | The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions |
title_sort | usefulness of c-kit in the immunohistochemical assessment of melanocytic lesions |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284155/ https://www.ncbi.nlm.nih.gov/pubmed/22193299 http://dx.doi.org/10.4081/ejh.2011.e20 |
work_keys_str_mv | AT pillonil theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT biancop theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT difelicee theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT cabrass theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT castellanosme theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT atzoril theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT ferrelic theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT mulasp theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT nemolatos theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT faag theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT pillonil usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT biancop usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT difelicee usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT cabrass usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT castellanosme usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT atzoril usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT ferrelic usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT mulasp usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT nemolatos usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions AT faag usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions |